Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced the appointment of Joseph V. Bonventre, M.D., Ph.D. to the Company's Board of Directors.

AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors

Cambridge, MA | Posted on February 27th, 2008

Dr. Bonventre holds appointments as the Robert H. Ebert Professor of Medicine at Harvard Medical School, in Cambridge, MA, and Professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT). He is Director of the Renal Division at Brigham & Women's Hospital in Boston, MA. Dr. Bonventre is a member of the Council of the American Society of Nephrology (ASN). He is Chair of the Kidney Group of the Harvard Stem Cell Initiative, co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women's Hospital Research Institute and co-chair of the Technology in Medicine Initiative at the Brigham and Women's Hospital.

"We are delighted to have Dr. Bonventre join our Board at this important time for the Company. His academic experience, participation on scientific and medical advisory boards of several companies and his long-standing involvement with the ASN further strengthens our organization," commented Brian J.G. Pereira, M.D., President and Chief Executive Officer of AMAG Pharmaceuticals, Inc. "We look forward to Dr. Bonventre's contributions and welcome him to the Board," concluded Dr. Pereira.

Prior to his current appointments at Harvard Medical School and MIT, Dr. Bonventre served as Co-Director, Harvard-MIT Division of Health Sciences and Technology. In addition to his B.S. with distinction in Engineering Physics from Cornell University, Dr. Bonventre holds M.D. and Ph.D. degrees in Biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology. Dr. Bonventre completed his internship and residencies in Medicine at Massachusetts General Hospital. He is published widely on kidney injury and repair.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Companyís key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration in December 2007 which was accepted for filing in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti Field Trials Demonstrate New Multicarrier Waveform for Rural, Maritime Broadband Radio: Field Trial in Orkney Islands Used New Filtered Multicarrier Waveform at 700MHz Band with Flexible Bandwidth Usage (Fragmented and Continuous Spectrum) December 18th, 2017

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Nanomedicine

Synthetic protein packages its own genetic material and evolves computationally designed protein assemblies are advancing research in synthetic life and in targeted drug delivery December 15th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Announcements

Leti Field Trials Demonstrate New Multicarrier Waveform for Rural, Maritime Broadband Radio: Field Trial in Orkney Islands Used New Filtered Multicarrier Waveform at 700MHz Band with Flexible Bandwidth Usage (Fragmented and Continuous Spectrum) December 18th, 2017

CubeSat Structures Competition Opens Space Design to Students of the World December 16th, 2017

Error-free into the quantum computer age December 15th, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Emmanuel Sabonnadiere is Letiís New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project